Status: Path 1 of [Dialog Information Services via Modem] ### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog) Trying 3106900061...Open DIALOG INFORMATION SERVICES PLEASE LOGON: ***** HHHHHHHH SSSSSSSS? ### Status: Signing onto Dialog ENTER PASSWORD: ****** HHHHHHHH SSSSSSS? ****** Welcome to DIALOG ### Status: Connected Dialog level 00.07.20D Last logoff: 07sep00 13:43:13 Logon file001 14sep00 11:33:16 *** ANNOUNCEMENT ** NEW FILE RELEASED ***Prous Science Daily Essentials (Files 458, 459) ***WIPO/PCT Patents Fulltext (File 349) UPDATING RESUMED ***TFSD Ownership Database (File 540) ***Datamonitor Market Research (File 761) ***Dissertation Abstracts Online (File 35)

RELOADED

***Canadian Business Directory (File 533)

***D&B International Dun's Market Identifiers (File 518)

***D&B European Dun's Market Identifiers (File 521)

***Kompass Canada (File 594)

***CANCERLIT (File 159)

FILES REMOVED

***Thomson Risk Management Database (File 325)

***Sacramento Bee (File 496)

***Kompass UK (File 591)

>>>Get immediate news with Dialog's First Release news service. First Release updates major newswire databases within 15 minutes of transmission over the wire. First Release provides full Dialog searchability and full-text features. To search First Release files in OneSearch simply BEGIN FIRST for coverage from Dialog's broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<< >>> of new databases, price changes, etc. <<<

KWIC is set to 50. HILIGHT set on as '*'

File 1:ERIC 1966-2000/Sep 07
(c) format only 2000 The Dialog Corporation

Set Items Description

?b 155, 5, 73

14sep00 11:33:30 User259876 Session D109.1 \$0.41 0.118 DialUnits File1

\$0.41 Estimated cost File1

```
$0.42 Estimated cost this search
     $0.42 Estimated total session cost 0.118 DialUnits
SYSTEM: OS - DIALOG OneSearch
  File 155:MEDLINE(R) 1966-2000/Nov W1
         (c) format only 2000 Dialog Corporation
        5:Biosis Previews (R) 1969-2000/Sep W3
         (c) 2000 BIOSIS
      73:EMBASE 1974-2000/Aug W2
        (c) 2000 Elsevier Science B.V.
*File 73: Update codes are currently undergoing readjustment.
For details type Help News73.
      Set Items Description
?s (genetic (w) immunization) or (DNA (w) vaccine)
         936629 GENETIC
         152867 IMMUNIZATION
421 GENETIC(W)IMMUNIZATION
        1532833 DNA
         181153 VACCINE
           1997 DNA (W) VACCINE
           2358 (GENETIC (W) IMMUNIZATION) OR (DNA (W) VACCINE)
?s (B-cell (w) epitope) or (T-cell (w) epitope)
           1047 B-CELL
          72518 EPITOPE
               0 B-CELL(W)EPITOPE
            2300 T-CELL
           72518 EPITOPE
               O T-CELL(W) EPITOPE
             0 (B-CELL (W) EPITOPE) OR (T-CELL (W) EPITOPE)
?s (T (w) cell (w) epitope) or (B (w) cell (w) epitope)
Processing
        3562823 T
         5139993 CELL
          72518 EPITOPE
           2599 T(W)CELL(W)EPITOPE
         1405199 B
         5139993
                 CELL
           72518 EPITOPE
            1185 B(W) CELL(W) EPITOPE
            3462 (T (W) CELL (W) EPITOPE) OR (B (W) CELL (W) EPITOPE)
      S3 -
?s s1 and s3
            2358 S1
            3462 S3
             16 S1 AND S3
?rd
...completed examining records
              11 RD (unique items)
      $5
?t s5/3,k/all
            (Item 1 from file: 155)
 5/3,K/1
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.
09564384 98301629
                                          increases immunogenicity and
 Boosting with recombinant
                               vaccinia
protective efficacy of malaria *DNA* *vaccine*.
  Sedegah M; Jones TR; Kaur M; Hedstrom R; Hobart P; Tine JA; Hoffman SL
                     Naval Medical Research Institute, Bethesda, MD
            Program,
  Malaria
20889-5607, USA.
  Proceedings of the National Academy of Sciences of the United States of
America (UNITED STATES) Jun 23 1998, 95 (13) p7648-53, ISSN 0027-8424
Journal Code: PV3
```

\$0.01 TYMNET

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Boosting with recombinant vaccinia increases immunogenicity and

protective efficacy of malaria *DNA* *vaccine*.

... IFN)-gamma-dependent protection of mice against challenge with Py sporozoites. Immunization with a multiple antigenic peptide, including the only reported H-2Kd-restricted CD8+ *T* *cell* *epitope* on the PyCSP (PyCSP CTL multiple antigenic peptide) and immunization with recombinant vaccinia expressing the PyCSP induced CTL but only modest to minimal protection. Mice...

5/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

08759545 96180188

Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes.

Ciernik IF; Berzofsky JA; Carbone DP

Simmons Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TX 75235, USA.

Journal of immunology (UNITED STATES) Apr 1 1996, 156 (7) p2369-75,

ISSN 0022-1767 Journal Code: IFB

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... of genetic expression constructs into living animals can effectively induce both humoral and cellular immunity to the expressed proteins. Here we test the effectiveness of *genetic* *immunization* with a minigene coding for single epitopes derived from mutant p53 or from HIV gp120. We show that when these constructs are delivered by particle...

... frame with the adenovirus E3 leader sequence to target the epitope to the endoplasmic reticulum, thus acting like a genetic adjuvant. We conclude that genetic *T* *cell* *epitope* immunization is an alternative to peptide-based techniques for eliciting an effective immune response targeted against a single defined epitope. in some cases, the fusion of the gene product of the *DNA* *vaccine* vector with an endoplasmic reticulum targeting sequence may enhance immune induction.

5/3,K/3 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

12256929 BIOSIS NO.: 200000010431

Effects of the configuration of a multi-epitope chimeric malaria *DNA* *vaccine* on its antigenicity to mice.

AUTHOR: Jiang Yanfang; Lin Chengtao; Yin Bin; He Xiangyun; Mao Yinghong;

Dong Min; Xu Pei; Zhang Lianhui; Liu Baofeng; Wang Heng(a)
AUTHOR ADDRESS: (a) No. 5 Dong Dan San Tiao, Rm. 562, Beijing, 100005**China

JOURNAL: Chinese Medical Journal (English Edition) 112 (8):p686-690 Aug.,

1999

ISSN: 0366-6999

DOCUMENT TYPE: Article RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

Effects of the configuration of a multi-epitope chimeric malaria *DNA* *vaccine* on its antigenicity to mice.

... ABSTRACT: using a pair of isocaudamers on the vector, different single

copies of B epitopes were multiplied and were tenderly stringed into two groups of chimeric *DNA* *vaccine* with different configurations. BALB/c mice were immunized with these DNA plasmids by either intramuscular or intradermal injections. Results: The antisera from the immunized mice...

... T helper cell epitopes configured with the B cell epitopes did not enhance antibody response, and some configurations even decreased the humoral response to a *B* *cell* *epitope*. Conclusion: This study demonstrated that both combination and configuration of the epitope may affect the antigenicity of a chimeric multiple antigen. DESCRIPTORS:

B *cell* *epitope*; ... CHEMICALS & BIOCHEMICALS:

...multi-epitope chimeric malaria *DNA* *vaccine*

(Item 2 from file: 5) 5/3,K/4 5:Biosis Previews(R) DIALOG(R)File (c) 2000 BIOSIS. All rts. reserv.

BIOSIS NO.: 199900321235 12040716

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.

AUTHOR: Gilbert Sarah C(a); Schneider Jorg; Plebanski Magdalena; Hannan Carolyn M; Blanchard Tom J; Smith Geoff L; Hill Adrian VS

AUTHOR ADDRESS: (a) Wellcome Trust Centre for Human Genetics, University of Oxford, Windmill Road, Oxford, OX3 7BN**UK

1999

JOURNAL: Biological Chemistry 380 (3):p299-303 March, 1999

ISSN: 1431-6730

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: Three types of vaccine, all expressing the same antigen from Plasmodium berghei, or a CD8+ *T* *cell* *epitope* from that antigen, were compared for their ability to induce CD8+ T cell responses in mice. Higher levels of lysis and numbers of IFN-gamma... DESCRIPTORS:

DNA *vaccine*; CHEMICALS & BIOCHEMICALS:

(Item 3 from file: 5) 5/3,K/5 DIALOG(R)File 5:Biosis Previews(R) (c) 2000 BIOSIS. All rts. reserv.

11657029 BIOSIS NO.: 199800438760

Protection by minigenes: A novel approach of DNA vaccines.

AUTHOR: Yu Zhiya(a); Karem Kevin L; Kanangat Sivadesan; Manickan

Elanchezhiyan; Rouse Barry T

AUTHOR ADDRESS: (a) Immunol. Dep., Mayo Clin., 828 Guggenheim Build., 200 First St. SW, Rochester, MN 55905**USA

1998

JOURNAL: Vaccine 16 (17):p1660-1667 Oct., 1998

ISSN: 0264-410X

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

DESCRIPTORS:

herpes simplex virus cytotoxic T and *B* CHEMICALS & BIOCHEMICALS: *cell* *epitope* minigene cassette...

MISCELLANEOUS TERMS: ...*DNA* *vaccine* development

(Item 4 from file: 5) 5/3,K/6 DIALOG(R) File 5: Biosis Previews (R) (c) 2000 BIOSIS. All rts. reserv.

BIOSIS NO.: 199698812555

Induction of cytotoxic T lymphocytes with a *DNA* *vaccine* expressing a single *T* *cell* *epitope* after gene transfer to the skin.

AUTHOR: Ciernik I F(a); Berzofsky J A; Carbone D

AUTHOR ADDRESS: (a) Cent. Hop. Univ. Vaudois, Lausanne 1011**Switzerland

JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 37 (0):p341 1996

CONFERENCE/MEETING: 87th Annual Meeting of the American Association for Cancer Research Washington, D.C., USA April 20-24, 1996

ISSN: 0197-016X

RECORD TYPE: Citation

LANGUAGE: English

Induction of cytotoxic T lymphocytes with a *DNA* *vaccine* expressing a single *T* *cell* *epitope* after gene transfer to the skin.

(Item 5 from file: 5) 5/3,K/7 5:Biosis Previews(R) DIALOG(R)File (c) 2000 BIOSIS. All rts. reserv.

09885615 BIOSIS NO.: 199598340533

Genetic *immunization* maps immune responses against a sequence shared between the EBV protein Balf2 and the pJRA-related HLA allele DRB1*0801. AUTHOR: La Cava Antonio(a); Xu Lan; Montemayor Ann; Carson Dennis A; Albani Salvatore

AUTHOR ADDRESS: (a) Dep. Pediatr. Med., Univ. Calif., San Diego, CA 92093-0663**USA

JOURNAL: Journal of Cellular Biochemistry Supplement 0 (21A):p123 1995 CONFERENCE/MEETING: Keystone Symposium on Control and Manipulation of the Immune Response Taos, New Mexico, USA March 16-22, 1995

ISSN: 0733-1959 RECORD TYPE: Citation LANGUAGE: English

Genetic *immunization* maps immune responses against a sequence shared between the EBV protein Balf2 and the pJRA-related HLA allele DRB1*0801. MISCELLANEOUS TERMS: ...*T*-*CELL* *EPITOPE*

(Item 1 from file: 73) 5/3,K/8 DIALOG(R)File 73:EMBASE (c) 2000 Elsevier Science B.V. All rts. reserv.

EMBASE No: 2000063895 10598657

Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: Different outcomes dependent on the plasmid DNA inoculation method

Toda M.; Sato H.; Takebe Y.; Taniguchi Y.; Saito S.; Inouye S.; Takemori

T.; Sakaguchi M.

Dr. M. Sakaguchi, National Inst. Infectious Diseases, Department of Immunology, Toyama 1-23-1, Shinjyuku-ku, Tokyo 162-8640 Japan Immunology (IMMUNOLOGY) (United Kingdom) 2000, 99/2 (179-186)

ISSN: 0019-2805 CODEN: IMMUA DOCUMENT TYPE: Journal; Article

SUMMARY LANGUAGE: ENGLISH LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 36

...gamma), but not interleukin (IL)-4, in vitro upon stimulation with Cry j 1 as well as with p277-288, a peptide corresponding to the *T*-*cell*

epitope of Cry j 1. In contrast, inoculation of BALB/c mice with pCACJ1 by gene gun injection caused response predominantly of the IgG1 type, and DRUG DESCRIPTORS: **DNA* *vaccine*; *immunoglobulin E--endogenous compound--ec; *plasmid DNA; *pollen antigen 5/3,K/9 (Item 2 from file: 73) DIALOG(R) File 73: EMBASE (c) 2000 Elsevier Science B.V. All rts. reserv. EMBASE No: 1999298477 Identification of amino acid residues of the *T*-*cell* *epitope* of Mycobacterium tuberculosis alpha antigen critical for Vbetallsup + Th1 cells Kariyone A.; Higuchi K.; Yamamoto S.; Nagasaka-Kametaka A.; Harada M.; Takahashi A.; Harada N.; Ogasawara K.; Takatsu K. K. Takatsu, Department of Immunology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639 Japan AUTHOR EMAIL: takatsuk@ims.u-tokyo.ac.jp Infection and Immunity (INFECT. IMMUN.) (United States) 1999, 67/9 (4312 - 4319)CODEN: INFIB ISSN: 0019-9567 DOCUMENT TYPE: Journal; Article LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH NUMBER OF REFERENCES: 54 Identification of amino acid residues of the *T*-*cell* *epitope* of Mycobacterium tuberculosis alpha antigen critical for Vbetallsup + Th1 cells DRUG DESCRIPTORS: *t lymphocyte receptor; **DNA* *vaccine*--drug development--dv; **DNA* *vaccine*--pharmaceutics--pr

5/3,K/10 (Item 3 from file: 73) DIALOG(R) File 73: EMBASE (c) 2000 Elsevier Science B.V. All rts. reserv.

EMBASE No: 1998156940 07274384

Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis

Lobell A.; Weissert R.; Storch M.K.; Svanholm C.; De Graaf K.L.; Lassmann H.; Andersson R.; Olsson T.; Wigzell H.

A. Lobell, Pharmacia and Upjohn, 112 87 Stockholm Sweden

AUTHOR EMAIL: anna.lobell@eu.pnu.com

Journal of Experimental Medicine (J. EXP. MED.) (United States) 04 MAY 1998, 187/9 (1543-1548)

ISSN: 0022-1007 CODEN: JEMEA DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 25

... is an autoaggressive disease in the central nervous system and an animal model for multiple sclerosis. Lewis rats were vaccinated with DNA encoding an encephalitogenic *T* *cell* *epitope*, guinea pig myelin basic protein peptide 68-85 (MBP68-85), before induction of EAE with MBP68-85 in complete Freund's adjuvant. Compared to vaccination... DRUG DESCRIPTORS:

*myelin basic protein--drug development--dv; *myelin basic protein--drug therapy--dt; *immunoglobulin fc fragment; **dna* *vaccine*--drug development--dv; **dna* *vaccine*--drug therapy--dt

```
(Item 4 from file: 73)
 5/3,K/11
DIALOG(R) File 73: EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.
             EMBASE No: 1997098358
 Melanoma vaccines: Prospects for the treatment of melanoma
  Hersey P.
  P. Hersey, Oncology and Immunology Unit, Department of Surgery, John
  Hunter Hospital, Cnr. King and Watt Streets, Newcastle, NSW 2300
  Expert Opinion on Investigational Drugs ( EXPERT OPIN. INVEST. DRUGS
  United Kingdom) 1997, 6/3 (267-277)
  CODEN: EOIDE
                 ISSN: 1354-3784
  DOCUMENT TYPE: Journal; Review
  LANGUAGE: ENGLISH
                      SUMMARY LANGUAGE: ENGLISH
  NUMBER OF REFERENCES: 95
  ...code for melanoma antigens. Experimental studies on the use of naked
DNA as vaccines are also proceeding. Several fundamental obstacles
preventing the effective use of *T*-*cell* *epitope* vaccines remain. These
include selection of HLA and tumour antigen loss variants by the immune
system, and conditioning of an ineffective immune response by the ...
DRUG DESCRIPTORS:
...endogenous compound-jec; bcg vaccine--drug therapy--dt; carmustine--drug
therapy--dt; cisplatin--drug therapy--dt; cyclophosphamide--drug therapy
--dt; cytokine; dacarbazine--drug therapy--dt; *dna* *vaccine*--drug
therapy--dt; *dna* *vaccine*--drug development--dv; epitope--endogenous
compound -- ec; granulocyte macrophage colony stimulating factor -- drug
therapy--dt; interferon--drug therapy--dt; interleukin 12--drug therapy--dt
; interleukin...
?ds
                Description
Set
        Items
                (GENETIC (W) IMMUNIZATION) OR (DNA (W) VACCINE)
S1
         2358
                (B-CELL (W) EPITOPE) OR (T-CELL (W) EPITOPE)
S2
S3
         3462
                (T (W) CELL (W) EPITOPE) OR (B (W) CELL (W) EPITOPE)
S4
           16
                S1 AND S3
$5
           11
                RD (unique items)
?s s5 and (coated (w) particle?)
              11 S5
           90804
                 COATED
          249948
                  PARTICLE?
             964
                  COATED (W) PARTICLE?
                 S5 AND (COATED (W) PARTICLE?)
?s s1 and (human)
Processing
            2358 S1
        15755829 HUMAN
            1164 S1 AND (HUMAN)
?s s7 and (ex (w) vivo (w) gene therapy)
            1164 S7.
           51913 EX
          810504 VIVO
           26603 GENE THERAPY
               0 EX(W) VIVO(W) GENE THERAPY
               O S7 AND (EX (W) VIVO (W) GENE THERAPY)
?s s1 and (human (w) trial)
Processing
            2358
                 S1
       15755829 HUMAN
          481510 TRIAL
            215 HUMAN (W) TRIAL
               1 S1 AND (HUMAN (W) TRIAL)
      59
```

'?t s9/3,k/all

```
DIALOG(R) File 73: EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.
           EMBASE No: 1998238264
07357024
 First *human* *trial* of a DNA-based vaccine for treatment of human
immunodeficiency virus type 1 infection: Safety and host response
  Macgregor R.R.; Boyer J.D.; Ugen K.E.; Lacy K.E.; Gluckman S.J.;
Bagarazzi M.L.; Chattergoon M.A.; Baine Y.; Higgins T.J.; Ciccarelli R.B.;
Coney L.R.; Ginsberg R.S.; Weiner D.B.
  Dr. R.R. Macgregor, Infectious Diseases Division, Univ. of Pennsylvania
  Sch. of Med., 536 Johnson Pavilion, Philadelphia, PA 19104-6073 United
  States*
  AUTHOR EMAIL: macgregr@mail.med.upenn.edu
  Journal of Infectious Diseases ( J. INFECT. DIS. ) (United States) 1998
  178/1 (92-100)
  CODEN: JIDIA ISSN: 0022=1899
  DOCUMENT TYPE: Journal; Article
  LANGUAGE: ENGLISH
                     SUMMARY LANGUAGE: ENGLISH
  NUMBER OF REFERENCES: 54
 First *human* *trial* of a DNA-based vaccine for treatment of human
immunodeficiency virus type 1 infection: Safety and host response
DRUG DESCRIPTORS:
**dna* *vaccine*--adverse drug reaction--ae; **dna* *vaccine*--clinical
trial--ct; **dna* *vaccine*--drug dose--do; **dna* *vaccine*--drug therapy
--dt; **dna* *vaccine*--pharmacology--pd; *human immunodeficiency virus
vaccine--adverse drug reaction--ae; *human immunodeficiency virus vaccine
--clinical trial--ct; *human immunodeficiency virus vaccine--drug dose--do;
*human...
?ds
Set
        Items
                Description
                (GENETIC (W) IMMUNIZATION) OR (DNA (W) VACCINE)
s1
         2358
                (B-CELL (W) EPITOPE) OR (T-CELL (W) EPITOPE)
S2
         3462
                (T (W) CELL (W) EPITOPE) OR (B (W) CELL (W) EPITOPE)
S3
S4
           16
                S1 AND S3
S5 -
           11
                RD (unique items)
S6
           0
                S5 AND (COATED (W) PARTICLE?)
S7
         1164
                S1 AND (HUMAN)
S8
                S7 AND (EX (W) VIVO (W) GENE THERAPY)
S9
                S1 AND (HUMAN (W) TRIAL)
           1
?s s1 and (ex (w) vivo )
           2358 S1
           51913 EX
          810504 VIVO
           28273 EX(W) VIVO
             26 S1 AND (EX (W) VIVO )
...completed examining records
              14 RD (unique items)
?t s11/3,k/all
 11/3,K/1
              (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.
           20322687
10455478
 Genetically modified dendritic cells prime autoreactive T cells through a
pathway independent of CD40L and interleukin 12: implications for cancer
vaccines.
 Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
             of Pathology and Molecular Medicine, Center for Gene
Therapeutics, McMaster University, Hamilton, Ontario, Canada.
Cancer research (UNITED STATES) Jun 15 2000, 60 (12) p3247-53, 0008-5472 Journal Code: CNF
 Languages: ENGLISH
```

Document type: JOURNAL ARTICLE

Genetic *immunization* through *ex* *vivo* transduction of dendritic cells has been suggested as an effective approach to enhance antitumor immunity by activating both CD4+ and CD8+ T cells. Immunizing mice...

11/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10452139 20182114

Quantitative and qualitative analyses of the immune responses induced by a multivalent minigene *DNA* *vaccine*.

An LL; Rodriguez F; Harkins S; Zhang J; Whitton JL

Department of Neuropharmacology, CVN-9, The Scripps Research Institute, La Jolla, CA 92037, USA.

Vaccine (ENGLAND) Apr 14 2000, 18 (20) p2132-41, ISSN 0264-410X Journal Code: X60

Contract/Grant No.: AI-37186, AI, NIAID

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Quantitative and qualitative analyses of the immune responses induced by a multivalent minigene *DNA* *vaccine*.

... intracellular cytokine staining, we show that immunization with a plasmid encoding a full-length protein induces epitope-specific CD8(+) T cells which are detectable directly *ex* *vivo*, and constitute approximately 2% of the vaccinee's splenic CD8(+) T cells. In contrast, such cells are undetectable directly *ex* *vivo* in recipients of a minigene vaccine. Nevertheless, the minigene plasmid does induce a low number of epitope-specific CD8(+) T cells, which can be amplified...

11/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10338462 20148953

Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization.

Hassett DE; Zhang J; Slifka M; Whitton JL

Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037, USA.

Journal of virology (UNITED STATES) Mar 2000, 74 (6) p2620-7, ISSN 0022-538X Journal Code: KCV

Contract/Grant No.: AI-37186, AI, NIAID

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... are maintained for a significant part of the animal's life span. We employ a sensitive technique which permits the first demonstration and quantitation, directly *ex* *vivo*, of virus-specific CD8(+) T cells induced by DNA immunization. One year postvaccination, antigen-specific CD8(+) T cells were readily detectable and constituted 0.5 to 1% of all CD8(+) T cells. By several criteria-including cytokine production, perforin content, development of lytic ability, and protective capacity-*DNA* *vaccine* -induced CD8(+) memory T cells were indistinguishable from memory cells induced by immunization with a conventional (live-virus) vaccine. Analyses of long-term humoral immune...

11/3,K/4 (Item 4 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09594262 98350799

The role of T cell subsets and cytokines in the regulation of intracellular bacterial infection.

Oliveira SC; Harms JS; Rech EL; Rodarte RS; Bocca AL; Goes AM; Splitter GA

Departamento de Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil. scozeus@mono.icb.ufmg.br

Brazilian journal of medical and biological research (BRAZIL) Jan 1998, 31 (1) p77-84, ISSN 0100-879X Journal Code: BOF

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... with B. abortus have demonstrated that protective immunity to brucellosis is especially dependent on CD8+ T cells. To target MHC class I presentation we transfected *ex* *vivo* a murine macrophage cell line with B. abortus genes and adoptively transferred them to BALB/c mice. These transgenic macrophage clones induced partial protection in...

... activate the protective T cell subset. Lastly, as a new strategy for priming a specific class I-restricted T cell response in vivo, we used *genetic* *immunization* by particle bombardment-mediated gene transfer.

11/3,K/5 (Item 5 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09266490 97378930

Protection against tuberculosis by a plasmid *DNA* *vaccine*.

Lowrie DB; Silva CL; Colston MJ; Ragno S; Tascon RE

NIMR, London, UK.

Vaccine (ENGLAND) Jun 1997, 15 (8) p834-8, ISSN 0264-410X

Journal Code: X60
Languages: ENGLISH

Document type: JOURNAL ARTICLE

Protection against tuberculosis by a plasmid *DNA* *vaccine*.

...cloned genes and suitable vectors has now opened a new avenue in which individual mycobacterial protein antigens are synthesised within transfected mammalian cells. In an *ex* *vivo* transfection approach with a retroviral vector we found that even a single antigen (hsp65) could evoke strong protection when expressed as a transgene and that...

11/3,K/6 (Item 6 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

08653710 96252198

Gene gun delivery of mRNA in situ results in efficient transgene expression and *genetic* *immunization*.

Qiu P; Ziegelhoffer P; Sun J; Yang NS

Department of Cancer Gene Therapy, Agracetus Inc, Middleton, WI 53562, USA.

Gene therapy (ENGLAND) Mar 1996, 3 (3) p262-8, ISSN 0969-7128 Journal Code: CCE

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Gene gun delivery of mRNA in situ results in efficient transgene expression and *genetic* *immunization*.

The use of mRNA to transfer genetic information into mammalian somatic cells in vivo or *ex* *vivo* may be advantageous in a number of gene therapy protocols. Success in utilizing in vivo RNA delivery for transgene expression has been extremely limited, partially...

11/3,K/7 (Item 7 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

08063691 95072131

Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.

Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn

AE; Peters G; Ronlov GS; Townsend KS; et al

Viagene, Inc., San Diego, CA 92121.

Human gene therapy (UNITED STATES)

Jul 1994, 5

(7) p853-62, ISSN

1043-0342 Journal Code: A12

Languages: ENGLISH

Document-type: JOURNAL-ART-IGLE-

... progression. The cellular immune response, in particular cytotoxic T lymphocyte (CTL) activity, may be important for eliminating virally infected cells in HIV-1-infected individuals. *Genetic* *immunization* using retroviral vectors provides an effective means of introducing antigens into the antigen presentation pathways for T cell stimulation. A nonreplicating, amphotropic murine retroviral vector...

... administered at 2-week intervals. The animals were evaluated for both the induction of HIV-1-specific immune responses and potential toxicity associated with this *ex* *vivo* treatment. The VTAF-immunized monkeys generated CTL responses specific for HIV-1 ENV/REV expressing autologous target cells, whereas, NTAF-immunized monkeys showed negligible CTL...

... expressing HIV-1 IIIB ENV/REV proteins to stimulate immune responses in a non-human primate model, and provides a basis for this form of *genetic* *immunization* in HIV-infected humans.

11/3,K/8 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

12370762 BIOSIS NO.: 200000124264

Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications.

AUTHOR: Romano Gaetano(a); Micheli Pietro; Pacilio Carmen; Giordano Antonio AUTHOR ADDRESS: (a) Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, 233 South 10th Street, 624 Bluemle Life Sciences Building, Philadelphia, PA, 19107**USA

2000

JOURNAL: Stem Cells (Miamisburg) 18 (1):p19-39 2000

ISSN: 1066-5099

DOCUMENT TYPE: Literature Review

RECORD TYPE: Abstract LANGUAGE: English

SUMMARY LANGUAGE: English

...ABSTRACT: to implement procedures of allogeneic tissues or cell transplantation. In addition, gene transfer technology has allowed for the development of innovative vaccine design, known as *genetic* *immunization*. This technique has already been applied in the AIDS vaccine programs in the USA. These programs aim to confer protective immunity against HIV-1 transmission...

MISCELLANEOUS TERMS: *ex*-*vivo* gene transfer...

...*genetic* *immunization*;

(Item 1 from file: 73) DIALOG(R)File 73:EMBASE (c) 2000 Elsevier Science B.V. All rts. reserv.

EMBASE No: 2000157301 10675987.

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

Allen T.M.; Vogel T.U.; Fuller D.H.; Mothe B.R.; Steffen S.; Boyson J.E.; Shipley T.; Fullers J.; Hanke T.; Sette A.; Altman J.D.; Moss B.; McMichael

A.J.; Watkins D.I.

Dr. T.M. Allen, Wisconsin Reg. Primate Res. Center, University of Wisconsin, Madison, WI 53715 United States

AUTHOR EMAIL: tallen@primate.wisc.edu

Journal of Immunology (J. IMMUNOL.) (United States) 01 MAY 2000, 164/9 (4968 - 4978)

ISSN: 0022-1767 CODEN: JOIMA DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 74

... frequency of Ag-specific cells, and intracellular IFN-gamma staining demonstrated that the majority of these cells produced IFN-gamma after peptide stimulation. Moreover, direct *ex* *vivo* SIV-specific cytotoxic activity could be detected in PBMC from live of the six DNA/MVA-vaccinated animals, indicating that this epitope-based DNA prime... DRUG DESCRIPTORS:

*Human immunodeficiency virus vaccine--drug development--dv; *Human immunodeficiency virus vaccine--pharmaceutics--pr; *Human immunodeficiency virus vaccine--pharmacology--pd; **DNA* *vaccine*--drug development--dv; *DNA* *vaccine*--pharmaceutics--pr; **DNA* *vaccine*--pharmacology--pd

(Item 2 from file: 73) 11/3,K/10 DIALOG(R) File 73: EMBASE (c) 2000 Elsevier Science B.V. All rts. reserv.

EMBASE No: 2000080577

Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen

Weissert R.; Lobell A.; De Graaf K.L.; Eltayeb S.Y.; Andersson R.; Olsson

T.; Wigzell H.

R. Weissert, Department of Neurology, University of Tuebingen, Hoppe-Seyler-Strasse 3, D-72076 Tuebingen Germany AUTHOR EMAIL: robert.weissert@uni-tuebingen.de Proceedings of the National Academy of Sciences of the United States of America (PROC. NATL. ACAD. SCI. U. S. A.) (United States) 15 FEB 2000

97/4 (1689-1694) CODEN: PNASA ISSN: 0027-8424 DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 19

... vaccination exquisitely discriminates between peptide target autoantigens. No bystander suppression was observed. The exact underlying mechanisms remain elusive because no simple correlation between impact on *ex* *vivo* responses and protection against disease were noted. DRUG DESCRIPTORS: **DNA* *vaccine*--drug therapy--dt; **DNA* *vaccine*--pharmacology--pd; myelin basic protein--endogenous compound--ec; *autoantigen

(Item 3 from file: 73) 11/3,K/11 DIALOG(R) File 73: EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

07893226 EMBASE No: 1999367010

Plasmid DNA vaccines are effective in the absence of IFNgamma

Hassett D.E.; Zhang J.; Whitton J.L.

J.L. Whitton, Department of Neuropharmacology, Scripps Research Institute, 10550 N. Torrey Pines Rd., San Diego, CA 92037 United States

AUTHOR EMAIL: lwhitton@scripps.edu

Virology (VIROLOGY) (United States) 10 OCT 1999, 263/1 (175-183)

CODEN: VIRLA ISSN: 0042-6822 DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 43

...positive (BALB/c) and IFNgamma-negative (GKO) mice responded to DNA vaccination by the development of antigen-specific CD8sup + T cells, which were detectable directly *ex* *vivo* by intracellular cytokine staining and comprised 0.7-2.5% of all CD8sup + T cells in the vaccinee. DNA vaccines also induced virus-specific, cytotoxic...
DRUG DESCRIPTORS:

**DNA* *vaccine*; *gamma interferon

'11/3,K/12 (Item 4 from file: 73)

DIALOG(R) File 73: EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

07863221 EMBASE No: 1999343601

DNA pulsed macrophage-mediated cDNA expression library immunization in vaccine development

Manoutcharian K.; Terrazas L.I.; Gevorkian G.; Govezensky T. K. Manoutcharian, Instituto Investigaciones Biomedicas, Universidad Nacional Autonoma, Ciudad Universitaria, Apartado Postal 70228, CP 04510 Mexico D.F. Mexico

AUTHOR EMAIL: karman@servidor.unam.mx

Vaccine (VACCINE) (United Kingdom) 1999, 18/5-6 (389-391)

CODEN: VACCD ISSN: 0264-410X

PUBLISHER ITEM IDENTIFIER: S0264410X9900239X

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 9

...s cDNA clones, has been previously used in our laboratory in an experimental model of murine Taenia crassiceps cysticercosis. In this study we show that *ex* *vivo* immunization of mice with macrophages pulsed in vitro with plasmid DNA containing cDNA expression library (2x10sup 4 clones) leads to significant reduction of parasite load...
DRUG DESCRIPTORS:

*complementary DNA; *plasmid *DNA*; **vaccine*--drug development--dv

11/3,K/13 (Item 5 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

07454921 EMBASE No: 1998364271

Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma

Paglia P.; Medina E.; Arioli I.; Guzman C.A.; Colombo M.P.

Dr. M.P. Colombo, Division of Experimental Oncology D, Ist. Naz. Studio e

Cura dei Tumori, Via Venezian 1, I-20133 Milano Italy

AUTHOR EMAIL: mcolombo@istitutotumori.mi.it

Blood (BLOOD) (United States) 01 NOV 1998, 92/9 (3172-3176)

CODEN: BLOOA ISSN: 0006-4971 DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...CD11c(bright) dendritic cells (DCs) were scored as positive for GFP expression. Extensive work has been performed trying to optimize the way to transfect DCs, *ex* *vivo*, with genes coding for relevant antigens. We show here, for the first time, that DCs can be directly and specifically transduced in vivo such to... DRUG DESCRIPTORS: *cancer vaccine; **dna* *vaccine* (Item 6 from file: 73) 11/3,K/14 DIALOG(R) File 73: EMBASE (c) 2000 Elsevier Science B.V. All rts. reserv. EMBASE No: 1998001081 07110119 Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: Cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization Boyle J.S.; Koniaras C.; Lew A.M. A.M. Lew, Burnet Clinical Research Unit, W and E Hall Inst. Medical Research, Melbourne, Vic. 3050 Australia International Immunology (INT. IMMUNOL.) (United Kingdom) 1997, 9/12 (1897 - 1906)CODEN: INIME ISSN: 0953-8178 DOCUMENT TYPE: Journal; Article SUMMARY LANGUAGE: ENGLISH LANGUAGE: ENGLISH NUMBER OF REFERENCES: 42 ...professional antigen-presenting cells. In contrast, intradermal immunization with cOVA produced optimal CTL responses but, as with mOVA, suboptimal antibody responses. This, together with our *ex* *vivo* RT-PCR analysis showing similar mRNA levels from all three constructs 7 days post-immunization, argues against the differential CTL response for i.m. injection... DRUG DESCRIPTORS: **dna* *vaccine* ?ds Description **Ttems** Set (GENETIC (W) IMMUNIZATION) OR (DNA (W) VACCINE) 2358 S1 (B-CELL (W) EPITOPE) OR (T-CELL (W) EPITOPE) S2 0 (T (W) CELL (W) EPITOPE) OR (B (W) CELL (W) EPITOPE) 3462 s3 S1 AND S3 S4 16 . 11 RD (unique items) S5 S5 AND (COATED (W) PARTICLE?) s6 S1 AND (HUMAN) **s**7 1164 S7 AND (EX (W) VIVO (W) GENE THERAPY) 0 **S8** S1 AND (HUMAN (W) TRIAL) **S9** 1 S1 AND (EX (W) VIVO) S10 26 RD (unique items) S11 14 ?s s1 and (coated (w) particle?) 2358 S1 90804 COATED 249948 PARTICLE? 964 COATED (W) PARTICLE? 4 S1 AND (COATED (W) PARTICLE?) ?rd ...completed examining records 2 RD (unique items) S13 ?t s13/3,k/all (Item 1 from file: 155) 13/3,K/1

DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

09527957 98285732

Protective immunity induced by oral immunization with a rotavirus *DNA* *vaccine* encapsulated in microparticles.

Chen SC; Jones DH; Fynan EF; Farrar GH; Clegg JC; Greenberg HB; Herrmann

JE.

Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.

Journal of virology (UNITED STATES) Jul 1998, 72 (7) p5757-61, ISSN 0022-538X Journal Code: KCV

Contract/Grant No.: R01 AI39637, AI, NIAID; R41 AI40449, AI, NIAID

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Protective immunity induced by oral immunization with a rotavirus *DNA*

vaccine encapsulated in microparticles.

DNA vaccines are usually given by intramuscular injection or by gene gun delivery of DNA-*coated* *particles* into the epidermis. Induction of mucosal immunity by targeting DNA vaccines to mucosal surfaces may offer advantages, and an oral vaccine could be effective for controlling infections of the gut mucosa. In a murine model, we obtained protective immune responses after oral immunization with a rotavirus VP6 *DNA* *vaccine* encapsulated in poly(lactide-coglycolide) (PLG) microparticles. One dose of vaccine given to BALB/c mice elicited both rotavirus-specific serum antibodies and intestinal immunoglobulin...

... that we obtained with PLG-encapsulated rotavirus VP6 DNA are the first to demonstrate protection against an infectious agent elicited after oral administration of a *DNA* *vaccine*.

13/3,K/2 (Item 1 from file: 73)

DIALOG(R) File 73: EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

07935567 EMBASE No: 1999409162

Gene gun approches for *DNA* *vaccine* and cytokine gene therapy in protozoan parasite infection

Sakai T.; Himeno K.

T. Sakai, Dept. of Parasitology and Immunology, Univ. of Tokushima Sch.

of Medicine, Tokushima Japan

Shikoku Acta Medica (SHIKOKU ACTA MED.) (Japan) 25 OCT 1999, 55/5 (180-185)

CODEN: SKIZA ISSN: 0037-3699 DOCUMENT TYPE: Journal; Article

LANGUAGE: JAPANESE SUMMARY LANGUAGE: ENGLISH; JAPANESE

NUMBER OF REFERENCES: 19

Gene gun approches for *DNA* *vaccine* and cytokine gene therapy in protozoan parasite infection

The particle-mediated method for gene delivery with a gun utilizes a shock wave to accelerate DNA-*coated* *particles* into target cells or tissues. This gene delivery method is effective in various somatic tissues in vitro and in vivo. We have, herein, applied this gene delivery system to *DNA* *vaccine* and cytokine gene therapy for protozoan parasite infections. We used cDNA encoding 47 kDa of Plasmodium falciparum serine repeat antigen (SERA) that is a vaccine...

...in vivo regulated systemic immune responses and furthermore this treatment and progression of experimental trypanosomiasis. Therefore, this gene gun approach may be a useful for *DNA* *vaccine* and gene therapy in a wide spectrum of diseases other than protozoan parasite infection.

DRUG DESCRIPTORS:

**DNA* *vaccine*--drug development--dv; *cytokine

```
Description
Set
      Items
            (GENETIC (W) IMMUNIZATION) OR (DNA (W) VACCINE)
S1
      2358
             (B-CELL (W) EPITOPE) OR (T-CELL (W) EPITOPE)
         0
S2
            (T (W) CELL (W) EPITOPE) OR (B (W) CELL (W) EPITOPE)
       3462
S3
        16
             S1 AND S3
        11
             RD (unique items)
             S5 AND (COATED (W) PARTICLE?)
         0
             S1 AND (HUMAN)
s7
       1164
       0 S7 AND (EX (W) VIVO (W) GENE THERAPY)
       1 S1 AND (HUMAN (W) TRIAL)
S9-
       26 S1 AND (EX (W) VIVO )
        14 RD (unique items)
S11
        4 S1 AND (COATED (W) PARTICLE?)
S12
         2 RD (unique items)
S13
?logoff
     14sep00 11:46:09 User259876 Session D109.2
          $3.80 1.189 DialUnits File155
             $2.00 10 Type(s) in Format 3
         $2.00 10 Types
    $5.80 Estimated cost File155
          $9.90 6 Types
   $18.15 Estimated cost File5
         $14.32 1.685 DialUnits File73
            $28.20 12 Type(s) in Format 3
         $28.20 12 Types
   $42.52 Estimated cost File73
          OneSearch, 3 files, 4.347 DialUnits FileOS
    $0.65 TYMNET
   $67.12 Estimated cost this search
   $67.54 Estimated total session cost 4.465 DialUnits
```

Status: Signed Off. (13 minutes)